



Drug Treatments for Autism

Guest Editor:

Dr. Maryam Ardalan

1. Neuropsychiatry Unit, Aarhus University, Aarhus, Denmark
2. Centre for Perinatal Medicine and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Deadline for manuscript submissions:

closed (31 May 2023)

Message from the Guest Editor

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with a prevalence of more than 1%, rising to 41% in extremely premature babies. Autism prevalence is approximately four times higher in males than females. Both environmental and genetic factors have a role in the incidence of autism. Apart from the etiological aspects of autism, treatment for the disorder is not optimal. There are several groups of autism symptoms (e.g., emotional and behavioral) which need to be treated separately, and thus there are several therapeutic approaches, such as pharmacological, educational and psychological. None of these methods are completely successful in the improvement of symptoms, especially on their own. Indeed, autism is a heterogeneous disorder which affects each person differently, and therefore people with autism have different treatment needs. In this context, this Special Issue aims to collect information about different pharmacotherapeutic approaches for autism by considering both clinical and preclinical studies to improve our knowledge on the possible pharmacotherapies currently available and identify future therapeutic targets for autism.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com